TWST:NASDAQTwist Bioscience Corporation Analysis

Twist Bioscience is trading at $91.55, comfortably above its 20‑day ($91.44) and 50‑day ($83.51) moving averages, which supports the algorithmic “bullish” trend label, but the MACD is bearish (line below signal, –1.06 histogram) and volume is on a downtrend, hinting at short‑term weakness. The stock’s beta of ~2.5 and 30‑day volatility of 68% signal a highly volatile, market‑sensitive instrument, while the Fear & Greed Index at 92.9 shows extreme greed in the broader market. Fundamentally, revenue grew 19% YoY to $409 M with a solid 52% gross margin, yet operating margins are –35% and the company burns ~ $58 M of free cash each quarter, leaving a modest cash cushion of $172 M against $111 M of debt. Valuation is stretched – price‑to‑book is 12.5× and price‑to‑sales 13.9×, far above the industry PE average of 29× (TWST reports a negative PE). Analyst sentiment remains positive (Buy consensus, median target $98.5) and recent fund buying (Parnassus Growth Equity) underscores confidence in the AI‑driven synthetic‑DNA market, but Evercore ISI’s downgrade to “In Line” tempers enthusiasm.